金十图示：2025年06月03日（周二）美股热门股票行情一览（美股盘初） VISA * 7111.01億市值 6730.59億市值 5251.65億市值 750.32 364.77 578.35 +3.20(+0.43%) -0.55(-0.15%) -2.88(-0.49%) 甲骨文 強生 P&G 資潔 4692.04億市值 3909.88億市值 3738.80億市值 155.39 167.32 166.76 +0.75(+0.45%) -1.01(-0.60%) -0.01(-0.01%) 家得實 美國銀行 (catal 可口可樂 1711 3684.12億市值 3316.66億市值 3075.40億市值 370.29 44.03 71.45 -0.04(-0.10%) -0.55(-0.76%) +2.33(+0.63%) 阿斯麥 T-Mobile US Inc 聯合健康 - ASML 2899.92億市值 2764.75億市值 2762.24億市值 737.36 243.50 304.50 -9.17(-1.23%) +0.43(+0.18%) -0.22(-0.07%) 通用電氣(US) 賽富時 c ...

Core Viewpoint - The article discusses the successful development and market entry of the innovative flu drug, Olanidavir, by Zhongsheng Pharmaceutical, which has managed to outperform the established flu medication, Oseltamivir, in clinical trials [3][4][7]. Industry Progress - Since the initiation of drug regulation reforms in 2015, China's biopharmaceutical industry has made significant advancements in drug development, achieving breakthroughs in several areas previously dominated by multinational companies [3]. - The emergence of valuable drug molecules from both new and established pharmaceutical companies is expected to create substantial economic and social value for China [3]. Company Development - Zhongsheng Pharmaceutical's Olanidavir is the first flu RNA polymerase PB2 protein inhibitor approved in China, marking a significant milestone in the company's innovation journey [4][17]. - The drug was developed over a decade, with a focus on addressing the limitations of existing treatments, particularly the resistance and side effects associated with Oseltamivir [6][19]. Clinical Trial Success - In head-to-head clinical trials, Olanidavir demonstrated a median symptom relief time and fever relief time shorter than that of Oseltamivir, with nearly a 10% reduction in illness duration [7]. - Olanidavir showed superior efficacy against flu viruses, including those resistant to Oseltamivir and the newer drug, Marbofloxacin [7][8]. Market Potential - The Chinese flu medication market is projected to reach approximately 20 billion yuan, with Olanidavir expected to capture a significant share [19]. - The overall market for flu medications in China is nearing 20 billion yuan in 2023 and is anticipated to grow to 26.91 billion yuan by 2028 [18][19]. Future Plans - Zhongsheng Pharmaceutical aims to explore licensing opportunities for Olanidavir in international markets, particularly in the U.S. and Belt and Road countries, despite facing challenges in conducting large-scale clinical trials abroad [18]. - The company is also preparing for negotiations regarding national health insurance coverage for Olanidavir [18].

Core Insights - The article discusses the approval of a new influenza drug, Anglatavir, by China's drug regulatory authority, which is the first innovative drug to outperform the widely used Oseltamivir in head-to-head trials [1][3] - The drug targets the PB2 protein of the influenza virus and has been in development for 10 years, with expectations of capturing a market share of 2 billion yuan [1][10] Company Overview - Zhongsheng Pharmaceutical's subsidiary, Zhongsheng Ruichuang, is responsible for the development of Anglatavir, which has been a significant shift from traditional pharmaceutical practices to innovative drug development [2][8] - The company faced challenges during the development process, particularly after Johnson & Johnson's failure in clinical trials for a similar drug, VX-787, which raised doubts among investors [6][9] Market Context - The influenza drug market in China has evolved significantly, with Oseltamivir and the newer drug, Marbofloxacin, dominating the market [2][3] - The market for antiviral drugs in China is approaching 20 billion yuan, with projections indicating growth to 26.91 billion yuan by 2028 [9][10] Clinical Trial Results - Phase III clinical trial results showed that Anglatavir significantly reduced the time to symptom relief and viral load compared to Oseltamivir, indicating its potential effectiveness [3][4] - Anglatavir demonstrated superior efficacy against strains resistant to both Oseltamivir and Marbofloxacin, suggesting a strong competitive advantage [3][4] Future Prospects - The company plans to explore licensing opportunities for Anglatavir in international markets, particularly in the U.S. and Belt and Road countries, despite facing challenges in conducting large-scale clinical trials abroad [9][10] - The drug is currently approved for adults with uncomplicated influenza, and a pediatric formulation is in the pipeline, which could further expand its market reach [10]

Group 1 - The core point of the news is the significant rise in the stock price of CSPC Pharmaceutical Group, driven by potential high-value licensing deals, indicating a surge in the value of Chinese innovative drugs [3][5]. - CSPC Pharmaceutical is in deep discussions with multiple independent third parties regarding three potential licensing collaborations, which could yield up to $5 billion in total payments, making it one of the highest licensing amounts for Chinese innovative drugs in 2025 [5][6]. - The market is particularly focused on CSPC's EGFR-ADC drug SYS6010, which has shown promising clinical trial results, including a 39.2% objective response rate and a 93.1% disease control rate in patients with EGFR mutation non-small cell lung cancer [6]. Group 2 - The potential buyers for the licensing deals are expected to be large multinational pharmaceutical companies, with Johnson & Johnson identified as a strong competitor due to its lack of an EGFR-targeting ADC drug [8]. - CSPC's innovative drug business is positioned as a growth driver despite a 21.9% year-on-year decline in traditional drug revenue in Q1 2025, with expected upfront payments from business expansions totaling approximately $2.1 million [8][9]. - The industry is experiencing a record wave of innovative drug licensing deals, with 24 transactions completed in the first five months of 2025, and total amounts exceeding $15.5 billion [9].

Pinterest Inc-A 福克斯-B 陶氏 229.26亿市值 212.83亿市值 205.27亿市值 50.99 29.04 31.45 -0.51(-0.99%) +0.03(+0.08%) +0.70(+2.47%) 西部数据 哈里伯顿 华纳音乐 182.74亿市值 136.75亿市值 172.33亿市值 52.38 20.05 26.23 +0.03(+0.06%) +0.18(+0.93%) -0.07(-0.25%) Dropbox Inc-A Lyft Inc-A IMAX Corp 80.00亿市值 66.04亿市值 14.89亿市值 15.70 27.71 28.42 -0.28(-1.75%) -0.24(-0.84%) -0.12(-0.43%) @ JIN10.COM 金十数据 | 一个交易工具 43.09 131.40 125.61 -0.04(-0.10%) -3.33(-2.58%) +0.73(+0.56%) 奧多比 CAT 卡特彼勒 Uber 优步 1767.37亿市值 1763.48亿市值 1658.38亿市值 414.68 84.33 352.61 +2.45(+0 ...

+1.63(+0.84%) +0.96(+0.20%) +0.05(+0.04%) 高露洁 力拓(US) 英国石油(US) _ 高重星 770.34亿市值 745.75亿市值 752.38亿市值 28.99 92.02 60.00 -0.16(-0.55%) -0.80(-1.32%) -0.41(-0.44%) 巴克莱 PayPal Holdings ...... 纽约梅隆银行 PayPal Inc 638.88亿市值 629.18亿市值 695.88亿市值 71.55 89.30 17.62 +0.07(+0.10%) -0.93(-1.03%) -0.29(-1.62%) 德意志银行 恩智浦半导体 纽蒙特 the state 0 ND 500.08亿市值 584.27亿市值 534.10亿市值 52.49 27.52 197.95 -0.21(-0.41%) -0.49(-1.75%) -0.95(-0.48%) 美国国际集团 GM 通用汽车 Phillips 66 AIG 478.57亿市值 464.71亿市值 464.44亿市值 48.34 113.95 83.04 -0.38(-0.33%) -0 ...

金十图示：2025年05月23日（周五）美股热门股票行情一览（美股盘中） 6537.40亿市值 5134.22亿市值 5055.79亿市值 354.30 565.41 1188.00 -3.67(-1.03%) +0.03(0.00%) -4.73(-0.83%) 埃克森美孚 甲骨文 P&G 宝浩 3872.42亿市值 4418.24亿市值 4361.14亿市值 155.52 102.52 165.17 -0.45(-0.44%) -1.79(-1.14%) +0.14(+0.08%) 强生 美国银行 ss) 家得宝 101 3669.74亿市值 3602.39亿市值 3248.50亿市值 152.52 362.44 43.13 -0.09(-0.06%) -3.69(-1.01%) -0.18(-0.42%) 阿斯麦 T-Mobile US Inc 可口可乐 (acabela ASML 2737.56亿市值 3084.44亿市值 2860.00亿市值 727.21 71.66 241.10 +0.52(+0.73%) -13.49(-1.82%) +0.28(+0.12%) 赛富时 t | 联合健康 cis ...

金十图示：2025年05月23日（周五）美股热门股票行情一览（美股盘初） @ JIN10.COM 金十数据 | 一个交易工具 IINTU D.UU -0.13(-0.74%) +0.41(+0.78%) -0.29(-1.05%) 恩智浦半导体 AG 美国国际集团 Phillips 66 ND 457.23亿市值 481.26亿市值 468.79亿市值 190.50 81.34 112.18 -6.01(-3.06%) -0.80(-0.71%) -0.68(-0.83%) 斯伦贝谢 © Torget 塔吉特 0 本田汽车 426.25亿市值 455.38亿市值 428.15亿市值 94.23 33.48 29.42 -0.83(-0.87%) -0.10(-0.34%) -0.27(-0.80%) 福特汽车 淡水河谷 Yum! Brands Ford Inc 412.37亿市值 405.53亿市值 402.42亿市值 10.37 9.50 144.78 -0.07(-0.67%) -0.08(-0.84%) -0.72(-0.50%) 瓦莱罗能源 2 367.94亿中值 易趣 ebay 402.42亿市值 ...

金十图示：2025年05月22日（周四）美股热门股票行情一览（美股盘初） 5076.63亿市值 422.55亿市值 170.15亿市值 569.37 1192.90 102.62 -1.04(-1.00%) -0.17(-0.03%) -1.73(-0.15%) 甲骨文 强生 P&G 宝浩 3881.27亿市值 3680.75亿市值 4410.92亿市值 165.54 157.29 152.98 +0.12(+0.07%) +0.12(+0.07%) -0.20(-0.13%) 家得宝 美国银行 (eget 可口可乐 111 3645.63亿市值 3248.12亿市值 3095.23亿市值 366.79 71.91 43.13 -4.05(-1.09%) -0.13(-0.29%) +0.06(+0.08%) T-Mobile US Inc 赛富时 t | 联合健康 2735.29亿市值 2730.40亿市值 2706.82亿市值 240.90 300.99 282.12 +0.14(+0.06%) -1.99(-0.66%) -0.17(-0.06%) IBM Crop (%) 通用电气(US) cisco ...

Macro and Strategy - April fiscal data shows tax revenue returning to positive growth at 1.9% YoY, while general expenditure growth accelerated to 12.9% YoY [8][9] - Key tax categories showed mixed results, with personal income tax growing significantly at 9% YoY, while corporate income tax declined to 4% YoY [8][9] Textile and Apparel Industry - Textile manufacturing continues to benefit from inventory optimization and order rebound, with revenue growth of 13.7% YoY in 2024, while apparel and home textiles saw a slowdown to 1.0% YoY [9][10] - In Q1 2025, textile manufacturing growth slowed to 8.2% YoY, while apparel and home textiles faced a 5.1% decline in revenue [9][10] - Major companies in manufacturing, such as Huayi and Shenzhou, reported strong orders and better profitability, while sports brands showed resilience compared to casual wear [9][10] Pharmaceutical Industry - Q1 2025 saw overall revenue growth slow for overseas pharmaceutical companies, with Eli Lilly and Novo Nordisk showing significant growth driven by GLP-1 drugs [15][16] - The U.S. drug pricing reform and macroeconomic uncertainties are impacting revenue forecasts for major pharmaceutical firms [15][16] Computer Industry - Major domestic companies like Alibaba and Tencent are significantly increasing capital expenditures, with Alibaba planning to invest over 380 billion RMB in cloud and AI infrastructure over the next three years [17][18] - There is a growing demand for computing power rental services, with several companies announcing related orders [17][18] Automotive Industry - April 2025 saw a total vehicle production and sales of 2.619 million and 2.590 million units respectively, with a year-on-year increase of 8.9% and 9.8% [19][20] - New energy vehicles accounted for 47.3% of total new vehicle sales, with production and sales growth of 43.8% and 44.2% YoY [19][20] - The market is witnessing a shift towards autonomous driving technologies, with Robotaxi commercial deployment accelerating [20][21] Building Materials Industry - The recent government policy is expected to accelerate urban renewal projects, benefiting local construction and decorative renovation companies [22][23] - Cement prices have seen a slight decline, while demand remains weak, indicating a cautious market outlook [23][24] Smart IoT Industry - The company focuses on IoT solutions and is expanding into AI infrastructure, with significant revenue contributions from its various business segments [26][27] - The global AI server market is projected to grow rapidly, driven by increasing demand for AI training and inference [28] Travel Industry - The company reported a 16.2% increase in revenue for Q1 2025, with strong growth in domestic hotel bookings and international travel [29][30] - The international platform is experiencing rapid growth, benefiting from favorable policies and increased travel demand [30][31] Gaming and E-commerce Industry - The company achieved a 30% revenue growth in Q1 2025, driven by strong performance in e-commerce and digital financial services [33][34] - The gaming segment also saw significant growth, with a notable increase in user engagement and revenue from popular titles [36][37]